Multiparameter flow cytometry MRD may be a useful complement to RQ-PCR in individual patient management.
Introduction
Mantle Cell Lymphoma (MCL) is characterized by an advanced stage of disease at diagnosis, with most patients demonstrating peripheral blood or bone marrow infiltration. Historically, overall survival was short, but use of monoclonal anti-CD20 antibody and intensive treatment, including high-dose cytarabine and autologous stem-cell transplantation (ASCT) have improved prognosis. [1] [2] [3] [4] [5] [6] [7] Novel strategies, such as maintenance or preemptive treatment, may improve progression free survival and prevent clinical relapse [8] [9] [10] but are best used in combination with precise, reproducible, quantification of minimal residual disease (MRD). 11 In the EU-MCL study, multivariate analysis showed that MRD status at the end of induction is one of the strongest independent prognostic factors. 2,11 Moreover, MRD-based preemptive rituximab therapy restored PCR-negativity in 81% of MCL patients. Multi-color flow cytometry (MFC) assays with at least 6 colors have been applied to MRD monitoring in acute lymphoblastic leukemia 13, 14 , multiple myeloma [15] [16] [17] , chronic lymphocytic leukemia 18 and hairy cell leukemia. 19 To date, there are no established criteria for MRD quantification by MFC in MCL. An MCL four-color panel using surface light chain restriction in the CD19+CD5+ subpopulation lacked sensitivity for MRD quantification, being inferior to consensus, qualitative PCR. 20 We therefore developed a single, eight-color MFC tube for use in MCL and performed a pilot study on samples collected prospectively for molecular RQ-PCR MRD monitoring in EU-MCL patients. We analyzed the suitability of 8-color MFC for regular MRD evaluation, with a view to preemptive treatment on MRD relapse.
Patients and samples
Patients with previously untreated, histologically confirmed MCL of Ann Arbor stages II-IV were registered to one of two randomized EU-MCL clinical trials according to age and eligibility to receive an ASCT: patients up to 65 years of age to the MCL Younger trial (NCT00209222) 2 and patients older than 60 years to the MCL Elderly trial (NCT00209209) 9 . Both protocols were approved by the institutional review boards of all participating institutions and were conducted according to the declaration of Helsinki. Peripheral blood (PB) and/or bone marrow (BM) samples were collected at diagnosis, midterm staging, end-of-induction and post-induction at 2-3-monthly intervals until clinical relapse in both trials 2,9,11 . Full details of treatment are given in supplementary data. Response duration (RD) was defined only for patients who achieved at least a partial response (PR) after induction treatment and was calculated as the period from the completion of induction to documented progression or death from any cause, which were both considered as an event.
Statistical analyses are detailed in supplementary data.
MRD analysis in France was centralized in 2 reference centers, one of which (Necker Hospital) performed the comparison presented here. The comparison of MFC and RQ-PCR was performed for patients with diagnostic and at least one follow-up.
The number of samples analyzed by these techniques is indicated in supplementary Table 1 .
Multiparameter Flow Cytometry
Eight-color MFC was performed prospectively at diagnosis on fresh cells after Ficollseparation, but on thawed cryopreserved cell for MRD samples. The cells were stained with a conjugated monoclonal antibody combination using CD3/CD14/CD56-(FITC), LAIR-1/CD305-(PE), CD19-(PeCy7), CD5-(PerCPCy5.5), CD11A-(APC), Lambda (Alexa700), Kappa (Pacific Blue) and CD45 (V500 Figure 1) .
PCR-based MRD analysis
DNA from PB or BM was extracted by standard techniques and identification of clonal IgH rearrangement assessed using qualitative IgH-VDJ FR1 and FR2
consensus PCR on DNA extracted from the mononuclear fraction used for MFC.
Gene scanning and sequence analyses (ABI prism automated sequencer Applied Biosystems, San Francisco, CA) and ASO clone specific PCR were performed as described 27 adapted for lymphoma 11 , with identification of minimal sensitivity and QR for each patient. The minimum sensitivity considered acceptable was 10 -4 (0.01%). Positive RQ-PCR MRD results were quantified if within the QR, and considered as BQR if below this range. All analyses were performed using a 1Ct RQ-PCR cut-off from background (see Supplementary Table S3 for between 0.1-0.9% and 13 up to 1%.
Assessment of MCL by RQ-PCR
At least one diagnostic PB, BM or lymph node sample was submitted for prospective RQ-PCR from 131 MCL patients, of which at least one MRD sample was available Qualitative PCR allowed identification of a distinct clonal peak which could be sequenced in 95% (99/104) of diagnostic samples with a MFC population >1%, but also in 9 samples for whom MFC was lower than 1% and 14 patients for whom MFC was not possible, including 7 lymph node DNA samples. In these patients, the diagnostic sample infiltration used for the patient-specific standard curves The Euro-MRD group defined two criteria for definition of BQR positivity, with a 3Ct or 1Ct difference from first background positivity. 27 Data reanalysis using these more restrictive criteria for positivity (supplementary Table 3 Table 4 ).
Although the number of patients is limited, these data suggest that regular 
Discussion
Monitoring MRD in MCL clearly has a place in prognostic evaluation, therapeutic next-generation sequencing strategies will improve informativity and sensitivity 30 also plead for a combined approach, as will the use of droplet digital PCR.
9
In practice, therapeutic modification is rarely based on a single MRD result. The Euro-MRD group defined two criteria for definition of BQR positivity, with either 3Ct or 1Ct difference from first background positivity. In the former setting the aim is to avoid false positive MRD results, whereas the latter aims to avoid false negative results. The difference is based on the minimal difference between the highest Ct value considered to represent MRD positivity and the lowest Ct value of the polyclonal PBLs used to assess specificity. Under maximum sensitivity conditions, as used here, the Ct value of at least one of the triplicates must be >1 Ct below the lowest Ct of background, whereas under therapy intensification conditions which aim to reduce false positive results, the Ct value of at least one of the triplicates must be >3Ct below the lowest Ct of background.
In order to assess the impact of these different cut-offs, we compared the 68 BQR samples using 3Ct and 1Ct cut-offs. As shown in Table S1 , the former led to 15 
